Emerging CAR T-Cell Therapies in Myeloma and Management of Key Toxicities

Download this slideset for expert perspectives on emerging strategies in the use of CAR T-cell therapy for patients with multiple myeloma, as well as a discussion of management of key toxicities associated with CAR T-cell therapy.
Noopur Raje, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 1.40 MB
Released: December 3, 2020

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Bristol-Myers Squibb

Related Content

On-demand Clinical Care Options (CCO) Webcast on corneal toxicity in patients receiving antibody-drug conjugate therapy for the treatment of cancer

Asim V. Farooq, MD
Program Director
Sagar Lonial, MD Anthony Perissinotti, PharmD, BCOP
Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: January 20, 2021 Expired: January 19, 2022

Read expert answers to clinician questions on optimizing the care of patients with CLL in today’s practice, from Clinical Care Options (CCO)

Ian W. Flinn, MD, PhD Susan M. O'Brien, MD John Pagel Headshot John Pagel, MD, PhD Released: January 15, 2021

Expert answers to clinician questions on current challenges in managing patients with myelodysplastic syndromes (MDS), from Clinical Care Options (CCO)

Guillermo Garcia-Manero, MD Rami S. Komrokji, MD Jamile Shammo, MD, FASCP, FACP Released: January 11, 2021

Brief expert slideset from Clinical Care Options (CCO) on how and when to test for NTRK fusions in patients with head and neck cancer

Aarti Bhatia, MD, MPH Released: January 5, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue